Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance

Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance

Fecha de publicación online: 15/12/2017 Fecha de publicación en papel: 1 Diciembre 2017 Revista: The Journal of Infectious Diseases

Abstract:

High-quality, simplified, and low-cost human immunodeficiency virus (HIV) drug resistance tests that are able to provide timely actionable HIV resistance data at individual, population, and programmatic levels are needed to confront the emerging drug-resistant HIV epidemic. Next-generation sequencing technologies embedded in automated cloud-computing analysis environments are ideally suited for such endeavor. Whereas NGS can reduce costs over Sanger sequencing, automated analysis pipelines make NGS accessible to molecular laboratories regardless of the available bioinformatic skills. They can also produce highly structured, high-quality data that could be examined by healthcare officials and program managers on a real-time basis to allow timely public health action. Here we discuss the opportunities and challenges of such an approach.

Autores: Marc Noguera-Julian, Dianna Edgil, P Richard Harrigan, Paul Sandstrom, Catherine Godfrey, Roger Paredes

Suscríbete a la newsletter

Back to Top
Irsi Caixa

Impulsado por:

'La Caixa' Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Miembro de:

Cerca

Con la colaboración de: